Last reviewed · How we verify
NT-501 CNTF Implant
At a glance
| Generic name | NT-501 CNTF Implant |
|---|---|
| Sponsor | Jeffrey L Goldberg |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of NT-501 Encapsulated Cell Therapy for Glaucoma Neuroprotection and Vision Restoration (PHASE2)
- A Study to Determine the Safety and Efficacy of NT-501 With MHFM (PHASE3)
- Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants (PHASE4)
- Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for Macular Telangiectasia (MacTel) (PHASE2)
- A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa (PHASE2)
- A Study of an Encapsulated Cell Technology (ECT) Implant for Patients With Atrophic Macular Degeneration (PHASE2)
- Safety Study to Evaluate Bilateral CNTF Implants in Subjects With MacTel Type 2 (PHASE2)
- A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NT-501 CNTF Implant CI brief — competitive landscape report
- NT-501 CNTF Implant updates RSS · CI watch RSS
- Jeffrey L Goldberg portfolio CI